Valeant Pharma (VRX) Names New Chief Quality Officer
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Louis W. Yu, Ph.D. has been appointed to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016.
Dr. Yu will report to Joseph C. Papa, Chairman and CEO of Valeant. As a new member of Valeant's Executive Committee, Dr. Yu will oversee all aspects of quality and regulatory compliance for all of Valeant's global businesses and operating sites.
Dr. Yu joins Valeant with more than 30 years of leadership experience in the Quality and R&D functions of generic and branded pharmaceutical companies. He was Executive Vice President, Global Quality & Compliance at The Perrigo Company from November 2006 to January 2016, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. He also served between May and September 2016 as the Senior Vice President, Global Quality and Compliance at AMRI, a contract development and manufacturing organization (CDMO) company.
"Delivering quality products leads to quality health outcomes, and that is what we are focused on at Valeant," said Joseph C. Papa, chief executive officer of Valeant. "Dr. Louis Yu is a great addition to our organization, and we are delighted to bring him into the company in the important new role of Chief Quality Officer. Dr. Yu's deep quality leadership experience at a number of branded and generic pharmaceutical companies gives him a deep understanding of what our customers and regulators need, and I look forward to working closely with him."
Dr. Yu said, "I appreciate the opportunity to lead Valeant's global quality function and am eager to help the company implement sustainable quality and compliance programs that will further strengthen its businesses."
Biography of Louis W. Yu, Ph. D.
Dr. Louis W. Yu is Chief Quality Officer, Global Quality of Valeant Pharmaceuticals, Inc.
Dr. Yu joined Valeant from AMRI where he was Senior Vice President, Global Quality and Compliance. From November 2006 to January 2016, he served as Executive Vice President, Global Quality and Compliance at The Perrigo Company, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. Previously, he served as the highest quality officer for CV Therapeutics, Forest Laboratories and Solvay Pharmaceuticals USA. Earlier in his career, he served in the Quality and R&D organizations for over 16 years at various Johnson & Johnson companies in positions of increasing responsibility. He has been an adjunct professor at the School of Pharmacy, the University of Wisconsin, and currently is an adjunct faculty at the Purdue Polytechnic Institute in West Lafayette. Dr. Yu earned a B.S. in chemistry from the University of Wisconsin, and a M.S. and Ph.D. in analytical chemistry from Rutgers University.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Valeant Pharma (VRX) Moves Off Lows on Bill Miller Comments
- Aerojet Rocketdyne (AJRD) Taps United Tech's Lundstrom as CFO
- First NBC Bank (FNBC) Disagrees with 'Unfounded Assertions' in the Market
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments, Short Sales
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!